Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
20 participants
INTERVENTIONAL
2025-12-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure
NCT01580553
Acute Oral Ketones or Carbohydrate Supplement Modify Heart Function in Heart Failure?
NCT05651529
Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure
NCT01474486
Micronutrient Supplementation in Patients With Heart Failure
NCT01005303
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Oral Levocarnitine (L-Carnitine), 2970mg daily dose (990mg taken 3 times a day) for 3 months.
Levocarnitine
Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levocarnitine
Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
* Age ≥ 18 years
* Able to speak and read English
* Willing and able to provide consent
Exclusion Criteria
* Currently undergoing renal replacement therapy of any kind
* Pregnant, breastfeeding or intending pregnancy
* History of seizures of any type
* Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
* Unable to provide consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chris McIntyre
Nephrologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chris McIntyre, MBBS DM
Role: PRINCIPAL_INVESTIGATOR
London Health Sciences Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
London Health Sciences Centre
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.